{
    "clinical_study": {
        "@rank": "99215", 
        "arm_group": {
            "arm_group_label": "Uncontrolled hypertension patients", 
            "description": "The study will enroll 500 patients planned to undergo a renal denervation procedure (with the 'EnligHTN\u2122 Renal Denervation System') for the treatment of their uncontrolled hypertension."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this observational study is to further evaluate the safety and performance of\n      the EnligHTN\u2122 Renal Denervation System in the treatment of patients with uncontrolled\n      hypertension in clinical routine practice."
        }, 
        "brief_title": "Observational Study of the EnligHTN Renal Denervation System in Patients With Uncontrolled Hypertension", 
        "completion_date": {
            "#text": "January 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Uncontrolled Hypertension", 
        "condition_browse": {
            "mesh_term": "Hypertension"
        }, 
        "detailed_description": {
            "textblock": "The EnligHTN European Observational study is designed to collect more data, critical to the\n      benefit of the therapy, within a clinical routine setting."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject is planned to undergo a renal denervation procedure for the treatment of\n             hypertension\n\n          -  Subject is \u226518 years of age at time of consent\n\n          -  Subject must be able and willing to provide written informed consent\n\n          -  Subject must be able and willing to comply with the required follow-up schedule\n\n          -  Subject has office SBP \u2265 140 mmHg\n\n          -  Subject has established hypertension (diagnosed \u226512 months prior to baseline) and is\n             on a guideline based drug regimen at a stable (\u2265 14 days) and a fully tolerated dose\n             consisting of \u22653 anti-hypertensive medications (including 1 diuretic), or subject has\n             documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives\n             (ACE-I/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to\n             take 3 anti-hypertensive drugs\n\n        Exclusion Criteria:\n\n          -  Subject has known significant renovascular abnormalities such as renal artery\n             stenosis > 30%\n\n          -  Subject has undergone prior renal angioplasty, renal denervation, indwelling renal\n             stents, and/or abdominal aortic stent grafts\n\n          -  Subject has a history of hemodynamically significant valvular heart disease\n\n          -  Subject has blood clotting abnormalities\n\n          -  Subject life expectancy is < 12 months, as determined by the Study Investigator\n\n          -  Subject is participating in another clinical study which has the potential to impact\n             his/her hypertension management (pharmaceutical/ device/ homeopathic)\n\n          -  Subject is pregnant, nursing, or of childbearing potential and is not using adequate\n             contraceptive methods\n\n          -  Subject has active systemic infection\n\n          -  Subject has known renal arteries with diameter(s) < 4 mm\n\n          -  Subject has an estimated GFR <45 mL/min per 1.73 m2 using the Modification of Diet in\n             Renal Disease (MDRD) formula\n\n          -  Subject had a renal transplant or is awaiting a renal transplant"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients with uncontrolled hypertension"
            }
        }, 
        "enrollment": {
            "#text": "500", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02006758", 
            "org_study_id": "CV-12-064-EU-HT"
        }, 
        "intervention": {
            "arm_group_label": "Uncontrolled hypertension patients", 
            "description": "The EnligHTN\u2122 Renal Denervation System is designed to deliver radiofrequency (RF) energy to the renal nerves to achieve targeted denervation. The system consists of the EnligHTN\u2122 RF Ablation Generator (generator), the EnligHTN\u2122 Renal Artery Ablation Catheter (ablation catheter), and the EnligHTN\u2122 Guiding Catheter (optional).", 
            "intervention_name": "EnligHTN\u2122 Renal Denervation System", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "December 16, 2013", 
        "location": {
            "contact": {
                "last_name": "Gianluca Patelli, M.D.", 
                "phone": "+39 35 3063551"
            }, 
            "facility": {
                "address": {
                    "city": "Alzano Lombardo", 
                    "country": "Italy", 
                    "state": "Lombardia", 
                    "zip": "24068"
                }, 
                "name": "Dr. Gianluigi Patelli"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Italy"
        }, 
        "number_of_groups": "1", 
        "official_title": "EnligHTN European Observational Study", 
        "overall_official": {
            "affiliation": "Hospital Juan Ramon Jimenez, Huelva, Spain", 
            "last_name": "Jos\u00e9 Diaz, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Italy: Ethics Committee", 
                "Greece: Ethics Committee"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Mean reduction in office Systolic BP", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02006758"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "St. Jude Medical", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "St. Jude Medical", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "December 2013"
    }
}